1269055-85-7 Usage
Uses
Used in Pharmaceutical Industry:
BenzaMide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorois used as a pharmaceutical intermediate for the development of therapeutic agents and pharmaceutical drugs. Its unique structure allows it to potentially target specific biological pathways and receptors, which can be leveraged to create new treatments for various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, BenzaMide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluoroserves as a key compound for research and development. Its potential biological activity and ability to interact with biological targets make it a promising candidate for further exploration and optimization to enhance its therapeutic potential.
Used in Drug Development Efforts:
BenzaMide, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorois utilized in drug development efforts to create novel pharmaceuticals with improved efficacy, safety, and selectivity. Its unique properties and potential interactions with biological targets make it a valuable component in the design and synthesis of new drug molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1269055-85-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,9,0,5 and 5 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1269055-85:
(9*1)+(8*2)+(7*6)+(6*9)+(5*0)+(4*5)+(3*5)+(2*8)+(1*5)=177
177 % 10 = 7
So 1269055-85-7 is a valid CAS Registry Number.
1269055-85-7Relevant academic research and scientific papers
From triclosan toward the clinic: Discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria
Gerusz, Vincent,Denis, Alexis,Faivre, Fabien,Bonvin, Yannick,Oxoby, Mayalen,Briet, Sophia,LeFralliec, Géraldine,Oliveira, Chrystelle,Desroy, Nicolas,Raymond, Cédric,Peltier, La?titia,Moreau, Fran?ois,Escaich, Sonia,Vongsouthi, Vanida,Floquet, Stéphanie,Drocourt, Elodie,Walton, Armelle,Prouvensier, Laure,Saccomani, Marc,Durant, Lionel,Genevard, Jean-Marie,Sam-Sambo, Vanessa,Soulama-Mouze, Coralie
, p. 9914 - 9928 (2013/01/16)
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically relevant Gram negative bacteria that is currently undergoing clinical trials.
NOVEL ANTIBACTERIAL HYDROXYPHENYL COMPOUND
-
Page/Page column 17-18, (2011/04/14)
The invention relates to a novel hydroxyphenyl compound, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound.
